In its upcoming report, Ashland (ASH) is predicted by Wall Street analysts to post quarterly earnings of $1.33 per share, reflecting an increase of 224.4% compared to the same period last year. Revenues are forecasted to be $518.74 million, representing a year-over-year increase of 0.1%.The consensus EPS estimate for the quarter has undergone a downward revision of 3.2% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial ...

- Presentation at ASH will Feature Results from the Phase 2a Trial of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia After Venetoclax Failure – - 50% Response Rate at the Selected Dose Level of 30 mg Twice a Week (BIW) – - 45 mg (Safety Dose) Once a Week of SLS009 Showed a Median Overall Survival (OS) of 5.5 Months vs. <2.5 Months with Standard of Care; 60 mg Once a Week and 30 mg BIW Median OS Not Reached - NEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“S ...

Core Insights - Lyell Immunopharma, Inc. is advancing a pipeline of next-generation CAR T-cell therapies targeting solid tumors and hematologic malignancies [1][3] - The company announced the presentation of initial clinical data for IMPT-314, a dual-targeting CD19/CD20 CAR T-cell therapy for large B-cell lymphoma, at the upcoming ASH Annual Meeting [1][2] Company Overview - Lyell is a clinical-stage company focused on developing CAR T-cell therapies enhanced with technology to generate T cells that resist exhaustion and maintain durable stemness [3] - The company is headquartered in South San Francisco, California, with additional facilities in Seattle and Bothell, Washington [3] Clinical Development - IMPT-314 has received Fast Track Designation from the U.S. FDA for treating relapsed/refractory aggressive B-cell lymphoma [2] - The presentation of IMPT-314's results will occur on December 9, 2024, at the San Diego Convention Center during the ASH Annual Meeting [2]

- CRG-023 is a CD19-, CD20-, CD22-targeting tri-specific CAR T product candidate designed with the goal of providing more patients with a broad range of B-cell malignancies with durable responses by addressing several known causes of relapse, resulting in a potential best-in-class CAR T-cell therapy - - First of its kind, tri-cistronic CAR T to express three independent CARs from a single vector, with each CAR having a distinct co-stimulatory domain – - Data demonstrated sustained anti-tumor activity and a ...

Core Insights - Kura Oncology announced that two abstracts featuring clinical data from the KOMET-007 trial of ziftomenib have been accepted for presentation at the ASH Annual Meeting in December 2024 [1][2] Group 1: Clinical Trial Details - KOMET-007 is a multicenter Phase 1 trial evaluating ziftomenib in combination with standard treatments for patients with NPM1-mutant and KMT2A-rearranged acute myeloid leukemia (AML) [2] - The Phase 1a dose-escalation portion of the study has shown that all four cohorts have cleared the highest dose and advanced to the Phase 1b expansion study at 600 mg [2] Group 2: Safety and Efficacy - Clinical data suggests ziftomenib has a potential best-in-class safety and tolerability profile, demonstrating robust activity in combination with standard care [3] - In the relapsed/refractory AML setting, ziftomenib combined with venetoclax/azacitidine has shown encouraging activity, with no dose-limiting toxicities or QTc prolongation reported [3] - In newly diagnosed adverse risk AML patients, 100% of NPM1-m patients and 84% of KMT2A-r patients remained on study approximately one year after the study start [3] Group 3: Upcoming Presentations - The oral presentation on ziftomenib combined with 7+3 will take place on December 7, 2024, at the San Diego Convention Center [4] - The poster presentation on ziftomenib combined with ven/aza is scheduled for December 8, 2024, at the same venue [4] Group 4: Company Overview - Kura Oncology is focused on precision medicines for cancer treatment, with ziftomenib being a key candidate targeting the menin-KMT2A interaction [5] - The company has received Breakthrough Therapy Designation for ziftomenib in treating relapsed/refractory NPM1-m AML and is conducting multiple clinical trials to evaluate its efficacy [5]

– Results from Phase 3 ENERGIZE-T Study of Mitapivat in Transfusion-dependent Thalassemia will be Presented in Oral Session – – Tebapivat Phase 1 Data in Sickle Cell Disease and Phase 2b Trial-in-progress Update in Lower-risk Myelodysplastic Syndromes will be Presented and Published – – Live and Webcast Investor Event with Agios Leadership and Medical Experts will be Hosted Onsite on Monday, December 9 – CAMBRIDGE, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader ...

INDIANAPOLIS, Nov. 5, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Jaypirca® (pirtobrutinib), a non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor, will be presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition taking place Dec. 7-10 in San Diego.In an oral presentation, Lilly will report results from the Phase 3 BRUIN CLL-321 study, which is evaluating pirtobrutinib versus idelalisib plus rituximab (IdelaR ...

Company Overview - Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing an innovative pipeline of cancer therapies [3] - The company's notable pipeline includes revumenib, a selective menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody targeting the colony stimulating factor 1 (CSF-1) receptor [3] Upcoming Event - The company will host an in-person investor event and live webcast on December 9, 2024, at 7:00 a.m. PT/10:00 a.m. ET during the 66th American Society of Hematology (ASH) Annual Meeting in San Diego, California [1] - Members of the Syndax management team will be joined by key opinion leaders to discuss data updates from the revumenib and Niktimvo™ programs [1] Webcast Availability - A live webcast of the event will be accessible on the investor section of the company's website, with a replay available for a limited time [2]

– New monotherapy and combination data in acute leukemia further highlight revumenib's compelling clinical profile –  – 64% ORR (62/97) in expanded dataset of patients with R/R KMT2Ar acute leukemia in Ph 2 AUGMENT-101 pivotal cohort ––  88% ORR (23/26) in SAVE trial testing revumenib, venetoclax and decitabine/cedazuridine combination in R/R AML –WALTHAM, Mass., Nov. 5, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq:SNDX) today announced that multiple abstracts evaluating revumenib, an oral small mole ...

Core Insights - Syndax Pharmaceuticals announced that multiple abstracts evaluating Niktimvo™ (axatilimab-csfr) for chronic graft-versus-host disease (GVHD) will be presented at the 66th American Society of Hematology (ASH) Annual Meeting [1][3] Group 1: Clinical Trial Results - The pivotal Phase 2 AGAVE-201 trial of Niktimvo showed a 75% overall response rate (ORR) among patients receiving the approved dose of 0.3 mg/kg every two weeks [4] - An estimated 60% of patients who responded maintained their response at 12 months [4] - More than half of responders in the 0.3 mg/kg cohort had an overall clinical response by day 56 of treatment [5] Group 2: Mechanism of Action and Safety - Preclinical data will be presented detailing the anti-inflammatory and anti-fibrotic mechanisms of axatilimab in chronic GVHD [8] - The exposure-efficacy analysis indicated that lower axatilimab exposure increased the odds of response, while higher exposure was associated with increased treatment-emergent adverse events [7] Group 3: Upcoming Presentations - An oral presentation titled "Dynamics of Overall and Organ-Specific Responses to Axatilimab in Chronic Graft-Versus-Host Disease" will take place on December 7, 2024 [6] - A poster presentation on "Exposure-Response Relationships for Axatilimab" is scheduled for the same day [8] Group 4: Company Collaboration and Future Directions - Syndax is collaborating with Incyte to advance the clinical development of Niktimvo for chronic GVHD and other inflammatory diseases [3] - The company is also exploring the use of axatilimab in combination with other therapies for chronic GVHD and idiopathic pulmonary fibrosis [13]